05.07.18
Atara Biotherapeutics has announced that Dietmar P. Berger, M.D., Ph.D. will join the company as global head of Research and Development.
“Dietmar is an accomplished physician-scientist and biotech research and development leader,” said Isaac Ciechanover, M.D., chief executive officer and president of Atara Biotherapeutics. “His deep experience building high-performing teams and strategic leadership of cancer immunotherapy development will help us shape the future of our innovative T-cell immunotherapy pipeline and technology platform.”
Prior to joining Atara, Dr. Berger was senior vice president and global head, Product Development, Clinical Science Hematology and Oncology at Roche/Genentech. In this role, he led medical strategy for the company’s global clinical development portfolio for cancer medicines, including global filings and approvals of Gazyva®, Cotellic®, Alecensa®, Tecentriq® and Hemlibra®.
“I am excited to join Atara and lead research and development during this transformational period, including the ongoing Phase 3 development of tab-cel™, the potential first commercially available off-the-shelf, allogeneic T-cell immunotherapy,” said Dr. Berger. "Together with Atara’s strong R&D leadership team, we will continue to focus on rigorous late-stage clinical development and leveraging the full potential of our technology platform.”
